SORRENTO THERAPEUTICS, INC. Form 8-K (Nov. 18, 2022)

Summary

Current report on Form 8-K for an event dated November 18, 2022, filed by Sorrento Therapeutics, Inc. Under Item 8.01, the report states that on November 18, 2022 the company announced that the board of directors has authorized the company to explore and consider a potential dividend to stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX) "currently held by the Company." The report states that there can be no assurance that the exploration will ultimately result in any such dividend. Any declaration and the timing are subject to conditions, including an evaluation of the potential legal and tax consequences, required filings and any required approvals or consents. Henry Ji signed on November 18, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): November 18, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On November 18, 2022,
Sorrento Therapeutics, Inc. (the “Company”) announced that its board of directors has authorized the Company to explore and
consider a potential dividend to the Company’s stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX) (the
“Scilex Common Shares”) currently held by the Company. However, there can be no assurance that the Company’s exploration
and consideration of any dividend of any Scilex Common Shares will ultimately result in any such dividend. In addition, any declaration,
as well as the potential timing, of any such dividend is subject to the satisfaction of a number of conditions, including an evaluation
and consideration of the potential legal and tax consequences of any such dividend to the Company and its stockholders, submission of
required filings, receipt of any approvals or consents determined to be required and other conditions that may be deemed to be applicable.

Forward-Looking Statements

This Current
Report on Form 8-K contains forward-looking statements related to the Company under
the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 that are based on management’s
beliefs and assumptions and on information currently available to the Company’s management and are subject to risks and uncertainties
that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the
Company’s exploration of any potential dividend of any Scilex Common Shares. Forward-looking statements include statements
that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “seek,” “should,” “will,” “would” or similar expressions and the
negatives of those terms. The Company’s actual results and the timing of events could materially differ from those anticipated in
such forward-looking statements as a result of certain risks and uncertainties. Such risks and uncertainties include the risk
that the Company may not ultimately pursue any dividend of any Scilex Common Shares, the risk that the Company’s exploration of any
potential dividend of Scilex Common Shares or the public announcement thereof may be disruptive to the Company’s business operations
or cause the Company’s stock price or the stock price of the Scilex Common Shares to fluctuate significantly, the risk that the
Company’s exploration of any potential dividend of Scilex Common Shares may be time consuming and involve the dedication of
significant resources and may require the Company to incur significant costs and expenses, the risk that the Company’s exploration
of any potential dividend of Scilex Common Shares could divert the attention of the Company’s management and its board of directors
from existing business operations, negatively impact the Company’s ability to attract, retain and motivate key employees, and expose
the Company to potential litigation in connection with the process of exploring any potential dividend of Scilex Common Shares, among
other risks and uncertainties, and other risks that are described in the Company’s most recent periodic reports filed with the Securities
and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent
Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings .
Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Current
Report on Form 8-K, and we undertake no obligation to update any forward-looking statement
in this Current Report on Form 8-K except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: November 18, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2022-11-18_0001104659-22-120026.htm

Size

28,533 bytes

SHA-256

aeb0b6714e46552545115ca39c924260099e351c710d496a293b7e5e5744b114

Our copy

SEC_SRNE_8-K_filed2022-11-18_0001104659-22-120026.htm

Original

www.sec.gov